Clicky

Friday, November 20, 2026
All public companies · Official EDGAR

ACETAdicet Bio, Inc.

Nasdaq · CIK 0001720580
Filer categoryNon-accelerated filer<br>Smaller reporting company
Entity typeoperating
SIC2834 Pharmaceutical Preparations
FY end1226
XBRL facts386

Identity from submissions API

NameAdicet Bio, Inc.
CIK0001720580
TickersACET
ExchangesNasdaq
Entity typeoperating
CategoryNon-accelerated filer<br>Smaller reporting company
SIC2834 Pharmaceutical Preparations
EIN813305277
LEI—
Fiscal year end1226
State of incorporationDE DE
Phone617-482-2333
Website—
Investor website—
Owner org03 Life Sciences
Flags—
Description—
Insider transactions (issuer)1
Insider transactions (owner)0

Former names

  • resTORbio, Inc. (2017-10-27T00:00:00.000Z → 2020-08-21T00:00:00.000Z)
Business address
131 DARTMOUTH STREET
3RD FLOOR
BOSTON
MA
02116
MA
Mailing address
131 DARTMOUTH STREET
3RD FLOOR
BOSTON
MA
02116
MA

EDGAR has no company-logo API. Website field is shown when the filer provided one.

Financialist coverage

SEC filings

683 filing rows loaded from submissions recent.

FiledFormDocumentItemsAccessionFile no.FilmActSizeXBRLiXBRL
2026-11-13 8-K 8-K 5.02 0001720580-26-000069 001-38359 261552285 34 155951 1 1
2026-11-05 10-Q 10-Q 0001720580-26-000066 001-38359 261527546 34 11110294 1 1
2026-11-05 8-K 8-K 2.02,9.01 0001720580-26-000065 001-38359 261527486 34 378167 1 1
2026-10-28 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000038777-26-000272 005-90283 261494507 34 30196
2026-10-23 SCHEDULE 13G xslSCHEDULE_13G_X02/primary_doc.xml 0002161951-26-000001 005-90283 261483166 34 8666
2026-09-28 8-K 8-K 7.01,8.01,9.01 0001720580-26-000060 001-38359 261412026 34 15801832 1 1
2026-09-08 8-K 8-K 7.01,9.01 0001720580-26-000056 001-38359 261365283 34 18688838 1 1
2026-09-01 8-K 8-K 7.01,9.01 0001720580-26-000054 001-38359 261348497 34 208922 1 1
2026-08-14 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001231919-26-000916 005-90283 261282848 34 15402
2026-08-07 4 4 0001776004-26-000003 5570
2026-08-05 10-Q 10-Q 0001720580-26-000050 001-38359 261243915 34 10920998 1 1
2026-08-05 8-K 8-K 2.02,9.01 0001720580-26-000049 001-38359 261243851 34 361183 1 1
2026-06-23 4 4 0001340875-26-000007 5606
2026-06-23 4 4 0001886986-26-000004 5605
2026-06-23 4 4 0001265123-26-000001 5514
2026-06-23 4 4 0001610876-26-000002 5553
2026-06-23 4 4 0001757601-26-000002 5530
2026-06-23 4 4 0001762451-26-000002 5537
2026-06-23 4 4 0001983850-26-000001 5518
2026-06-23 4 4 0001776004-26-000001 5529
2026-06-18 8-K 8-K 5.07 0001720580-26-000043 001-38359 261102407 34 180317 1 1
2026-05-20 10-K/A 10-K/A 0001720580-26-000042 001-38359 261004095 34 3498635 1 1
2026-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0000919574-26-003239 005-90283 26982853 34 9021
2026-05-13 S-8 POS S-8 POS 0001720580-26-000038 333-249275 26974593 33 182428
2026-05-13 10-Q 10-Q 0001720580-26-000037 001-38359 26973955 34 9751748 1 1
2026-05-13 8-K 8-K 2.02,9.01 0001720580-26-000036 001-38359 26973151 34 304835 1 1
2026-04-29 4 xslF345X06/form4-04292026_040403.xml 0001231919-26-000425 14326
2026-04-29 ARS ARS 0001720580-26-000029 001-38359 26915957 34 2859564
2026-04-29 DEFA14A DEFA14A 0001720580-26-000028 001-38359 26915754 34 1033965 1 1
2026-04-29 DEF 14A DEF 14A 0001720580-26-000027 001-38359 26915676 34 3986368 1 1
2026-04-28 8-K 8-K 3.02,9.01 0001720580-26-000023 001-38359 26907474 34 282864 1 1
2026-04-13 SCHEDULE 13G/A xslSCHEDULE_13G_X02/primary_doc.xml 0001346824-26-000105 005-90283 26858581 34 15069
2026-04-13 4 xslF345X06/form4-04132026_090451.xml 0001231919-26-000337 15718
2026-04-13 3 xslF345X06/form3-04132026_090419.xml 0001231919-26-000335 12089
2026-04-10 SCHEDULE 13D/A xslSCHEDULE_13D_X02/primary_doc.xml 0000947871-26-000427 005-90283 26856222 34 49162
2026-04-09 4 xslF345X06/ownership.xml 0000947871-26-000421 30345
2026-04-09 144 xsl144X01/primary_doc.xml 0000947871-26-000420 001-38359 26852659 33 4934
2026-04-08 144 xsl144X01/primary_doc.xml 0000947871-26-000417 001-38359 26849562 33 4986
2026-04-07 144 xsl144X01/primary_doc.xml 0000947871-26-000413 001-38359 26846228 33 5056
2026-03-27 4 4 0001519432-26-000002 5547
2026-03-27 4 4 0001340875-26-000003 5550
2026-03-27 4 4 0002052749-26-000003 5558
2026-03-27 4 4 0001643067-26-000002 5540
2026-03-27 4 4 0001886986-26-000002 5546
2026-03-23 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-26-000910 333-294265 26784031 33 1829
2026-03-19 CORRESP filename1.htm 0001720580-26-000017 18405
2026-03-18 UPLOAD filename1.pdf 0000000000-26-002754 333-294265 40117
2026-03-12 S-8 S-8 0001720580-26-000014 333-294266 26749044 33 346677 1 1
2026-03-12 S-3 S-3 0001720580-26-000013 333-294265 26749009 33 2243685 1 1
2026-03-12 10-K 10-K 0001720580-26-000008 001-38359 26748189 34 17944203 1 1
2026-03-12 8-K 8-K 2.02,9.01 0001720580-26-000006 001-38359 26748091 34 309006 1 1
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001346824-26-000031 005-90283 26641600 34 15431
2026-02-17 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-26-002017 005-90283 26641472 34 14211
2026-02-17 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000902664-26-001061 005-90283 26640195 34 9158
2026-01-29 SCHEDULE 13G xslSCHEDULE_13G_X01/primary_doc.xml 0000038777-26-000021 005-90283 26575860 34 25474
2026-01-27 4 4 0001193125-26-024755 4924
2026-01-27 4 4 0001193125-26-024753 4918
2026-01-27 4 4 0001193125-26-024749 6782
2026-01-27 4 4 0001193125-26-024746 4925
2026-01-07 8-K 8-K 7.01,8.01,9.01 0001193125-26-005486 001-38359 26514079 34 225155 1 1
2025-12-29 8-K 8-K 5.03,8.01,9.01 0001193125-25-332343 001-38359 251603350 34 232777 1 1
2025-12-19 8-K 8-K 5.07 0001193125-25-326784 001-38359 251587454 34 161175 1 1
2025-11-17 DEF 14A DEF 14A 0001193125-25-284586 001-38359 251490991 34 1685827 1 1
2025-11-05 PRE 14A PRE 14A 0001193125-25-266928 001-38359 251454031 34 1681235 1 1
2025-11-05 10-Q 10-Q 0001193125-25-266880 001-38359 251453889 34 10917902 1 1
2025-11-05 8-K 8-K 2.02,9.01 0001193125-25-266860 001-38359 251453786 34 348652 1 1
2025-10-10 4 xslF345X05/ownership.xml 0000947871-25-000898 26293
2025-10-10 SCHEDULE 13D/A xslSCHEDULE_13D_X01/primary_doc.xml 0000947871-25-000897 005-90283 251389030 34 48544
2025-10-07 8-K 8-K 3.01 0001193125-25-233427 001-38359 251379808 34 156969 1 1
2025-10-07 8-K 8-K 1.01,9.01 0001193125-25-232558 001-38359 251378247 34 1041495 1 1
2025-10-07 424B5 424B5 0001193125-25-232551 333-285609 251378240 33 2417460
2025-10-07 8-K 8-K 8.01,9.01 0001193125-25-232539 001-38359 251378226 34 19535157 1 1
2025-08-07 10-Q 10-Q 0000950170-25-104978 001-38359 251193855 34 11518431 1 1
2025-08-07 8-K 8-K 2.02,9.01 0000950170-25-104969 001-38359 251193802 34 336705 1 1
2025-07-25 S-8 S-8 0000950170-25-098771 333-288953 251151650 33 326298 1 1
2025-07-23 8-K 8-K 2.05,8.01,9.01 0000950170-25-097881 001-38359 251143071 34 304536 1 1
2025-06-13 4 4 0000950170-25-086166 7460
2025-06-13 4 4 0000950170-25-086163 7483
2025-06-13 4 4 0000950170-25-086160 7308
2025-06-13 4 4 0000950170-25-086157 7448
2025-06-13 4 4 0000950170-25-086135 7467
2025-06-13 8-K 8-K 5.07 0000950170-25-086120 001-38359 251046329 34 171977 1 1
2025-05-15 SCHEDULE 13G/A xslSCHEDULE_13G_X01/primary_doc.xml 0001214659-25-007867 005-90283 25953321 34 28705
2025-05-06 10-Q 10-Q 0000950170-25-064448 001-38359 25917256 34 9659106 1 1
2025-05-06 8-K 8-K 2.02,9.01 0000950170-25-064423 001-38359 25917149 34 305635 1 1
2025-04-29 ARS ARS 0000950170-25-060130 001-38359 25887671 34 3324581
2025-04-29 DEFA14A DEFA14A 0000950170-25-060115 001-38359 25887470 34 1698722 1 1
2025-04-29 DEF 14A DEF 14A 0000950170-25-060104 001-38359 25887415 34 6303033 1 1
2025-04-21 4 4 0000950170-25-056294 5391
2025-04-21 3 3 0000950170-25-056290 14799
2025-04-17 8-K 8-K 5.02,7.01,9.01 0000950170-25-054995 001-38359 25844285 34 195709 1 1
2025-04-11 8-K 8-K 3.01 0000950170-25-053238 001-38359 25831510 34 158354 1 1
2025-03-26 S-8 POS S-8 POS 0000950170-25-045304 333-249275 25773720 33 243742
2025-03-18 424B5 424B5 0000950170-25-041128 333-285609 25748147 33 360219
2025-03-14 EFFECT xslEFFECTX01/primary_doc.xml ,, 9999999995-25-000695 333-285609 25742150 33 1836
2025-03-12 CORRESP filename1.htm 0000950170-25-037893 14243
2025-03-11 UPLOAD filename1.pdf 0000000000-25-002651 333-285609 40095
2025-03-06 S-8 S-8 0000950170-25-034851 333-285610 25716110 33 402647 1 1
2025-03-06 S-3 S-3 0000950170-25-034844 333-285609 25716081 33 2534069
2025-03-06 10-K 10-K 0000950170-25-034587 001-38359 25715167 34 15800931 1 1
2025-03-06 8-K 8-K 2.02,9.01 0000950170-25-034580 001-38359 25715128 34 321565 1 1
2025-02-05 8-K 8-K 8.01 0000950170-25-014153 001-38359 25590844 34 163376 1 1
2025-02-04 4 4 0000950170-25-013611 5413
2025-02-04 4 4 0000950170-25-013607 5410
2025-02-04 4 4 0000950170-25-013602 5387
2025-02-04 4 4 0000950170-25-013596 5504
2025-02-04 4 4 0000950170-25-013591 5414
2025-01-28 4 4 0000950170-25-009843 7203
2025-01-28 4 4 0000950170-25-009839 4745
2025-01-28 4 4 0000950170-25-009838 4771
2025-01-28 4 4 0000950170-25-009827 4772
2025-01-23 3 3 0000950170-25-008323 14896
2024-12-19 8-K 8-K 7.01,8.01,9.01 0000950170-24-138419 001-38359 241563244 34 194186 1 1
2024-11-27 8-K 8-K 1.02 0000950170-24-131609 001-38359 241512361 34 152009 1 1
2024-11-18 8-K 8-K 7.01,8.01,9.01 0000950170-24-127927 001-38359 241471414 34 227127 1 1
2024-11-15 8-K 8-K 1.01,9.01 0000950170-24-127560 001-38359 241467745 34 213427 1 1
2024-11-14 SC 13G/A SC 13G/A 0001104659-24-119283 005-90283 241464717 34 93012
2024-11-14 SC 13G/A formsc13g.htm 0001493152-24-045800 005-90283 241461790 34 88030
2024-11-14 SC 13G/A AMENDMENT NO. 2 0001214659-24-019102 005-90283 241461368 34 136782
2024-11-14 SC 13G/A ADICET BIO, INC. 0000902664-24-006484 005-90283 241456805 34 65807
2024-11-13 SC 13G/A COWEN FINANCIAL PRODUCTS LLC 0001085146-24-005617 005-90283 241453737 34 27343
2024-11-06 10-Q 10-Q 0000950170-24-122253 001-38359 241430828 34 8282565 1 1
2024-11-06 8-K 8-K 2.02,9.01 0000950170-24-122244 001-38359 241430790 34 312115 1 1
2024-10-16 8-K 8-K 7.01,8.01,9.01 0000950170-24-114839 001-38359 241373265 34 193524 1 1
2024-10-08 SC 13G/A ACET_SC13GA1.htm 0001273087-24-000093 005-90283 241360687 34 81772
2024-09-30 8-K 8-K 7.01,8.01,9.01 0000950170-24-110166 001-38359 241336628 34 190851 1 1
2024-09-19 8-K 8-K 7.01,8.01,9.01 0000950170-24-107988 001-38359 241309070 34 194061 1 1
2024-09-10 8-K 8-K 8.01 0000950170-24-104915 001-38359 241288730 34 157163 1 1
2024-08-23 4 4 0000950170-24-100180 24775
2024-08-23 4 4 0000950170-24-100179 20522
2024-08-23 4 4 0000950170-24-100178 8012
2024-08-23 4 4 0000950170-24-100176 20568
2024-08-23 4 4 0000950170-24-100174 20396
2024-08-23 4 4 0000950170-24-100173 16672
2024-08-23 4 4 0000950170-24-100165 20503
2024-08-20 4 4 0000950170-24-099073 5400
2024-08-20 3 3 0000950170-24-099068 16694
2024-08-19 8-K 8-K 5.02,7.01,9.01 0000950170-24-098485 001-38359 241220348 34 187343 1 1
2024-08-13 10-Q 10-Q 0000950170-24-095745 001-38359 241198731 34 7707037 1 1
2024-08-13 8-K 8-K 2.02,9.01 0000950170-24-095744 001-38359 241198722 34 282371 1 1
2024-07-10 SC 13G/A MS AMENDMENT 0000895421-24-000393 005-90283 241110041 34 12903
2024-07-08 8-K 8-K 7.01,9.01 0000950170-24-081943 001-38359 241103339 34 174250 1 1
2024-06-24 8-K 8-K 7.01,8.01,9.01 0000950170-24-076460 001-38359 241061956 34 187307 1 1
2024-06-07 4 4 0000950170-24-070632 5414
2024-06-07 4 4 0000950170-24-070630 5386
2024-06-07 4 4 0000950170-24-070628 5415
2024-06-07 4 4 0000950170-24-070619 5388
2024-06-07 4 4 0000950170-24-070618 5414
2024-06-07 4 4 0000950170-24-070616 16453
2024-06-07 4 4 0000950170-24-070613 7493
2024-06-07 4 4 0000950170-24-070610 10057
2024-06-07 4 4 0000950170-24-070608 7321
2024-06-07 4 4 0000950170-24-070605 8848
2024-06-07 4 4 0000950170-24-070577 7460
2024-06-07 4 4 0000950170-24-070575 7480
2024-06-07 8-K 8-K 5.02,5.03,5.07,9.01 0000950170-24-070568 001-38359 241029182 34 507240 1 1
2024-06-05 144 xsl144X01/primary_doc.xml 0001972362-24-000846 001-38359 241023034 33 4314
2024-06-05 8-K 8-K 7.01,9.01 0000950170-24-069067 001-38359 241020691 34 171146 1 1
2024-05-14 10-Q 10-Q 0000950170-24-059507 001-38359 24944217 34 7161109 1 1
2024-05-14 8-K 8-K 2.02,9.01 0000950170-24-059496 001-38359 24944135 34 245444 1 1
2024-05-10 8-K 8-K 7.01,9.01 0000950170-24-057429 001-38359 24932741 34 10167100 1 1
2024-04-26 DEFR14A DEFR14A 0000950170-24-049136 001-38359 24883898 34 3905706 1 1
2024-04-24 ARS ARS 0000950170-24-047195 001-38359 24866486 34 3900725
2024-04-23 DEFA14A DEFA14A 0000950170-24-047044 001-38359 24865637 34 1382299
2024-04-23 DEF 14A DEF 14A 0000950170-24-047034 001-38359 24865615 34 3881905 1 1
2024-04-22 8-K 8-K 7.01,8.01,9.01 0000950170-24-046459 001-38359 24861582 34 200925 1 1
2024-04-12 PRE 14A PRE 14A 0000950170-24-044147 001-38359 24842470 34 2664517 1 1
2024-03-22 8-K 8-K 1.01,9.01 0000950170-24-035366 001-38359 24775427 34 591738 1 1
2024-03-22 424B5 424B5 0000950170-24-035357 333-263587 24775334 33 703024
2024-03-21 SC 13D/A AMENDMENT NO. 7 0000947871-24-000300 005-90283 24771853 34 257698
2024-03-19 S-8 POS S-8 POS 0000950170-24-033524 333-249275 24763646 33 165768
2024-03-19 S-8 S-8 0000950170-24-033502 333-278063 24763548 33 167688
2024-03-19 10-K 10-K 0000950170-24-033482 001-38359 24763399 34 12242966 1 1
2024-03-19 8-K 8-K 2.02,9.01 0000950170-24-033476 001-38359 24763349 34 301061 1 1
2024-02-27 SC 13G ACET_SC13G.htm 0001273087-24-000052 005-90283 24687301 34 81865
2024-02-14 SC 13G/A acet13ga.htm 0000935836-24-000201 005-90283 24638960 34 44951
2024-02-14 SC 13G/A AMENDMENT NO. 1 0001214659-24-002857 005-90283 24637373 34 87351
2024-02-14 SC 13G/A ADICET BIO, INC 0000902664-24-001558 005-90283 24632301 34 63567
2024-02-12 SC 13G MS INITIAL 0000895421-24-000186 005-90283 24617873 34 12760
2024-02-07 SC 13G/A us0070021086_020724.txt 0001086364-24-006832 005-90283 24605718 34 12569
2024-02-07 SC 13D/A SC 13D/A 0001193125-24-026734 005-90283 24604767 34 190465
2024-02-05 SC 13G SC 13G 0001104659-24-010651 005-90283 24596154 34 88807
2024-02-02 SC 13G/A COWEN FINANCIAL PRODUCTS LLC 0001085146-24-000635 005-90283 24589482 34 27376
2024-01-31 SC 13G/A us0070021086_013124.txt 0001086364-24-005988 005-90283 24582115 34 13477
2024-01-29 SC 13D/A AMENDMENT NO. 6 0000947871-24-000074 005-90283 24574413 34 263868
2024-01-26 4 4 0000950170-24-008053 26846
2024-01-26 4 4 0000950170-24-008052 14717
2024-01-26 4 4 0000950170-24-008051 8887
2024-01-26 4 4 0000950170-24-008050 8914
2024-01-26 4 4 0000950170-24-008049 8888
2024-01-26 4 4 0000950170-24-008048 8915
2024-01-26 4 4 0000950170-24-008046 10691
2024-01-24 8-K 8-K 1.01,2.02,8.01,9.01 0000950170-24-007011 001-38359 24556928 34 1168399 1 1
2024-01-24 424B5 424B5 0000950170-24-007007 333-263587 24556913 33 862857
2024-01-23 SC 13G/A Adicet_Bio_Inc.txt 0000093751-24-000085 005-90283 24550733 34 8472
2024-01-22 424B5 424B5 0000950170-24-006074 333-263587 24549175 33 852573
2024-01-19 SC 13G formsc13g.htm 0001493152-24-003061 005-90283 24545598 34 97046
2024-01-16 8-K 8-K 7.01,9.01 0000950170-24-004403 001-38359 24533622 34 23364387 1 1
2024-01-04 8-K 8-K 7.01,8.01,9.01 0000950170-24-001490 001-38359 24509757 34 638465 1 1
2023-11-13 8-K 8-K 5.02 0000950170-23-063062 001-38359 231399559 34 163670 1 1
2023-11-08 10-Q 10-Q 0000950170-23-061128 001-38359 231388025 34 8636052 1 1
2023-11-08 8-K 8-K 2.02,9.01 0000950170-23-061121 001-38359 231387982 34 353137 1 1
2023-10-16 4 FORM 4 SUBMISSION 0001209191-23-052845 4918
2023-10-03 4 FORM 4 SUBMISSION 0001209191-23-051473 4890
2023-10-03 4 FORM 4 SUBMISSION 0001209191-23-051470 4892
2023-10-03 4 FORM 4 SUBMISSION 0001209191-23-051468 4919
2023-10-02 4 FORM 4 SUBMISSION 0001209191-23-051259 13688
2023-09-29 144 xsl144X01/primary_doc.xml 0001950047-23-004316 001-38359 231296411 33 4779
2023-08-16 4 FORM 4 SUBMISSION 0001209191-23-046103 32981
2023-08-16 4 FORM 4 SUBMISSION 0001209191-23-046102 33451
2023-08-16 4 FORM 4 SUBMISSION 0001209191-23-046101 28411
2023-08-16 4 FORM 4 SUBMISSION 0001209191-23-046100 26171
2023-08-16 4 FORM 4 SUBMISSION 0001209191-23-046099 26140
2023-08-16 4 FORM 4 SUBMISSION 0001209191-23-046098 23610
2023-08-16 4 FORM 4 SUBMISSION 0001209191-23-046097 27700
2023-08-16 4 FORM 4 SUBMISSION 0001209191-23-046096 27699
2023-08-16 4 FORM 4 SUBMISSION 0001209191-23-046095 18294
2023-08-16 4 FORM 4 SUBMISSION 0001209191-23-046094 22673
2023-08-16 4 FORM 4 SUBMISSION 0001209191-23-046093 22780
2023-08-16 4 FORM 4 SUBMISSION 0001209191-23-046091 22845
2023-08-16 4 FORM 4 SUBMISSION 0001209191-23-046090 8738
2023-08-09 S-8 POS S-8 POS 0000950170-23-040656 333-249275 231155611 33 297196
2023-08-09 S-8 S-8 0000950170-23-040646 333-273834 231155579 33 363679
2023-08-09 10-Q 10-Q 0000950170-23-040631 001-38359 231155498 34 9269815 1 1
2023-08-09 8-K 8-K 2.02,9.01 0000950170-23-040617 001-38359 231155410 34 385045 1 1
2023-07-11 4 FORM 4 SUBMISSION 0001209191-23-042018 5360
2023-07-11 3 FORM 3 SUBMISSION 0001209191-23-042015 7509
2023-07-11 8-K 8-K 5.02,7.01,9.01 0000950170-23-032449 001-38359 231081255 34 206083 1 1
2023-06-30 4 FORM 4 SUBMISSION 0001209191-23-040299 4853
2023-06-29 4 xslF345X04/ownership.xml 0000947871-23-000714 16145
2023-06-29 4 xslF345X04/ownership.xml 0000947871-23-000713 29431
2023-06-29 SC 13D/A AMENDMENT NO. 5 0000947871-23-000710 005-90283 231057821 34 242833
2023-06-26 8-K 8-K 7.01,8.01,9.01 0000950170-23-029851 001-38359 231042337 34 470684 1 1
2023-06-05 8-K 8-K 1.01,9.01 0000950170-23-026406 001-38359 23993379 34 218326 1 1
2023-06-05 8-K 8-K 5.02,5.07,9.01 0000950170-23-026198 001-38359 23990462 34 424750 1 1
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033961 7795
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033960 7777
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033959 7785
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033958 10359
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033957 7750
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033956 7623
2023-06-02 4 FORM 4 SUBMISSION 0001209191-23-033955 9978
2023-05-18 8-K 8-K 7.01,8.01,9.01 0000950170-23-022865 001-38359 23933630 34 225769 1 1
2023-05-09 10-Q 10-Q 0000950170-23-019700 001-38359 23902283 34 8291291 1 1
2023-05-09 8-K 8-K 2.02,9.01 0000950170-23-019685 001-38359 23902168 34 323462 1 1
2023-04-18 ARS ARS 0000950170-23-013298 001-38359 23827249 34 2215042
2023-04-18 DEF 14A DEF 14A 0000950170-23-013294 001-38359 23827202 34 1656157
2023-04-18 DEFA14A DEFA14A 0000950170-23-013291 001-38359 23827165 34 186299
2023-03-15 S-8 S-8 0000950170-23-008138 333-270560 23735294 33 229825
2023-03-15 10-K 10-K 0000950170-23-008130 001-38359 23735208 34 14571857 1 1
2023-03-15 8-K 8-K 2.02 0000950170-23-008122 001-38359 23735150 34 381054 1 1
2023-03-13 SC 13G r38231sc13g.htm 0001214659-23-003784 005-90283 23727233 34 93808
2023-03-10 8-K 8-K 7.01 0000950170-23-007252 001-38359 23723430 34 175528 1 1
2023-02-17 4 FORM 4 SUBMISSION 0001209191-23-010936 5270
2023-02-14 5 FORM 5 SUBMISSION 0001209191-23-009588 20426
2023-02-14 4 FORM 4 SUBMISSION 0001209191-23-009177 5272
2023-02-14 SC 13G/A SC 13G/A 0001104659-23-021797 005-90283 23630746 34 73608
2023-02-14 SC 13G/A d9940889_13g-a.htm 0000919574-23-001489 005-90283 23625764 34 163114
2023-02-14 SC 13G/A ADICET BIO, INC. 0000902664-23-001704 005-90283 23623786 34 64212
2023-02-13 SC 13G us0070021086_021323.txt 0001306550-23-008656 005-90283 23617959 34 13306
2023-02-03 SC 13G Adicet_Bio_Inc.txt 0000093751-23-000157 005-90283 23585209 34 8476
2023-01-26 4 FORM 4 SUBMISSION 0001209191-23-005044 7562
2023-01-26 4 FORM 4 SUBMISSION 0001209191-23-005043 7591
2023-01-26 4 FORM 4 SUBMISSION 0001209191-23-005041 7564
2023-01-26 4 FORM 4 SUBMISSION 0001209191-23-005040 7590
2023-01-26 4 FORM 4 SUBMISSION 0001209191-23-005033 8476
2023-01-11 SC 13G/A COWEN FINANCIAL PRODUCTS LLC 0001085146-23-000071 005-90283 23522842 34 27292
2022-12-23 SC 13G acet13g.htm 0000935836-22-000658 005-90283 221483006 34 47132
2022-12-12 8-K 8-K 7.01,8.01,9.01 0000950170-22-026329 001-38359 221456062 34 797812 1 1
2022-12-08 8-K 8-K 1.01,9.01 0000950170-22-026232 001-38359 221452495 34 258872 1 1
2022-11-15 4 FORM 4 SUBMISSION 0001209191-22-057005 4815
2022-11-15 4 FORM 4 SUBMISSION 0001209191-22-057004 7473
2022-11-10 8-K 8-K 7.01,9.01 0000950170-22-024573 001-38359 221378478 34 5331114 1 1
2022-11-09 4 FORM 4 SUBMISSION 0001209191-22-056193 6098
2022-11-08 424B5 424B5 0000950170-22-023341 333-254193 221370014 33 728831
2022-11-08 10-Q 10-Q 0000950170-22-023230 001-38359 221369096 34 10269503 1 1
2022-11-08 8-K 8-K 2.02,9.01 0000950170-22-023224 001-38359 221369049 34 418864 1 1
2022-11-04 4 FORM 4 SUBMISSION 0001209191-22-055828 7824
2022-11-03 8-K 8-K 7.01,8.01,9.01 0000950170-22-021598 001-38359 221356461 34 243785 1 1
2022-10-21 4 FORM 4 SUBMISSION 0001209191-22-054261 5338
2022-10-17 SC 13G SC 13G 0001104659-22-109351 005-90283 221314013 34 80798
2022-10-14 4 FORM 4 SUBMISSION 0001209191-22-053659 10820
2022-10-05 8-K 8-K 8.01,9.01 0000950170-22-019282 001-38359 221294550 34 347634 1 1
2022-10-04 4 FORM 4 SUBMISSION 0001209191-22-052383 5775
2022-10-04 4 FORM 4 SUBMISSION 0001209191-22-052380 4888
2022-10-04 4 FORM 4 SUBMISSION 0001209191-22-052376 4861
2022-10-04 4 FORM 4 SUBMISSION 0001209191-22-052378 4859
2022-09-16 4 FORM 4 SUBMISSION 0001209191-22-050372 5701
2022-09-13 4 FORM 4 SUBMISSION 0001209191-22-049721 12174
2022-08-11 SC 13D/A SC 13D/A 0001193125-22-218665 005-90283 221156758 34 229521
2022-08-10 10-Q 10-Q 0000950170-22-016254 001-38359 221150388 34 9448936 1 1
2022-08-10 8-K 8-K 2.02,9.01 0000950170-22-016250 001-38359 221150374 34 441110 1 1
2022-08-08 4 FORM 4 SUBMISSION 0001209191-22-044905 12083
2022-08-08 4 FORM 4 SUBMISSION 0001209191-22-044904 7058
2022-08-08 4 FORM 4 SUBMISSION 0001209191-22-044903 7090
2022-08-08 4 FORM 4 SUBMISSION 0001209191-22-044902 7087
2022-08-08 4 FORM 4 SUBMISSION 0001209191-22-044901 7060
2022-08-05 4 FORM 4 SUBMISSION 0001209191-22-044646 4815
2022-08-03 4 FORM 4 SUBMISSION 0001209191-22-044182 5338
2022-07-07 4 FORM 4 SUBMISSION 0001209191-22-041499 5079
2022-06-21 8-K 8-K 1.01,9.01 0000950170-22-011916 001-38359 221028981 34 444689 1 1
2022-06-06 8-K 8-K 7.01,8.01,9.01 0000950170-22-011219 001-38359 22998029 34 502661 1 1
2022-06-03 4 FORM 4 SUBMISSION 0001209191-22-034103 5492
2022-06-03 4 FORM 4 SUBMISSION 0001209191-22-034097 5524
2022-06-03 4 FORM 4 SUBMISSION 0001209191-22-034092 5519
2022-06-03 4 FORM 4 SUBMISSION 0001209191-22-034088 5527
2022-06-03 4 FORM 4 SUBMISSION 0001209191-22-034082 5537
2022-06-03 4 FORM 4 SUBMISSION 0001209191-22-034079 5365
2022-06-03 4 FORM 4 SUBMISSION 0001209191-22-034072 5472
2022-06-03 8-K 8-K 5.07 0000950170-22-011172 001-38359 22995019 34 204339 1 1
2022-05-26 8-K 8-K 7.01,8.01,9.01 0000950170-22-010791 001-38359 22971238 34 253373 1 1
2022-05-12 4 FORM 4 SUBMISSION 0001209191-22-028567 5581
2022-05-12 10-Q 10-Q 0000950170-22-009690 001-38359 22918192 34 8986803 1 1
2022-05-12 8-K 8-K 2.02,9.01 0000950170-22-009682 001-38359 22918084 34 354935 1 1
2022-05-09 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2022-05-09 16:01:00 9999999995-22-001370 333-263587 22907169 33 1785
2022-05-05 CORRESP filename1.htm 0000950170-22-007926 15936
2022-05-05 8-K 8-K 7.01 0000950170-22-007552 001-38359 22893978 34 200924 1 1
2022-04-22 SC 13G COWEN FINANCIAL PRODUCTS LLC 0001085146-22-001519 005-90283 22845416 34 27222
2022-04-21 DEFA14A DEFA14A 0000950170-22-005929 001-38359 22841936 34 146666
2022-04-21 DEF 14A DEF 14A 0000950170-22-005928 001-38359 22841901 34 1049243
2022-04-19 8-K 8-K 7.01 0000950170-22-005777 001-38359 22833448 34 188656 1 1
2022-04-05 4 FORM 4 SUBMISSION 0001209191-22-023285 26284
2022-03-24 8-K 8-K 1.01,9.01 0000950170-22-004583 001-38359 22767483 34 540327 1 1
2022-03-16 UPLOAD filename1.pdf 0000000000-22-002920 40237
2022-03-16 S-3/A S-3/A 0001564590-22-010673 333-263587 22745785 33 176134
2022-03-16 S-8 S-8 031522 0001564590-22-010481 333-263588 22742445 33 216040
2022-03-15 S-3 S-3 0001564590-22-010479 333-263587 22742434 33 1818152
2022-03-15 10-K 10-K 0000950170-22-003753 001-38359 22741300 34 21087356 1 1
2022-03-15 8-K 8-K 2.02,9.01 0000950170-22-003745 001-38359 22741184 34 310599 1 1
2022-03-11 4 FORM 4 SUBMISSION 0001209191-22-018158 7754
2022-02-17 4 FORM 4 SUBMISSION 0001209191-22-010952 8151
2022-02-16 4 FORM 4 SUBMISSION 0001209191-22-010487 7058
2022-02-16 4 FORM 4 SUBMISSION 0001209191-22-010485 7088
2022-02-16 4 FORM 4 SUBMISSION 0001209191-22-010483 7056
2022-02-16 4 FORM 4 SUBMISSION 0001209191-22-010479 7085
2022-02-16 4 FORM 4 SUBMISSION 0001209191-22-010475 7087
2022-02-14 4 FORM 4 SUBMISSION 0001209191-22-009417 16790
2022-02-14 5 FORM 5 SUBMISSION 0001209191-22-009370 15923
2022-02-14 SC 13G/A d9178689_13g-a.htm 0000919574-22-001009 005-90283 22623507 34 170234
2022-02-03 8-K 8-K 8.01 0000950170-22-000704 001-38359 22586511 34 186168 1 1
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006142 7054
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006139 7056
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006136 7086
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006134 7083
2022-02-01 4 FORM 4 SUBMISSION 0001209191-22-006132 7085
2022-01-11 4 FORM 4 SUBMISSION 0001209191-22-002900 5529
2022-01-11 4 FORM 4 SUBMISSION 0001209191-22-002895 5582
2022-01-11 4 FORM 4 SUBMISSION 0001209191-22-002880 5501
2022-01-11 4 FORM 4 SUBMISSION 0001209191-22-002867 5503
2022-01-11 4 FORM 4 SUBMISSION 0001209191-22-002860 5527
2021-12-15 SC 13G formsc13g.htm 0001493152-21-031547 005-90283 211493922 34 172425
2021-12-14 4 xslF345X03/ownership.xml 0000947871-21-001281 13180
2021-12-14 4 xslF345X03/ownership.xml 0000947871-21-001280 25548
2021-12-14 SC 13D/A AMENDMENT NO. 4 0000947871-21-001279 005-90283 211492088 34 242810
2021-12-13 4/A xslF345X03/adicetbio_fm4amdec82021.xml 0000905718-21-001591 6612
2021-12-10 4 xslF345X03/adicetbio_fm4dec82021.xml 0000905718-21-001587 6366
2021-12-10 8-K 8-K 1.01,8.01,9.01 0000950170-21-005140 001-38359 211485592 34 788617 1 1
2021-12-09 424B5 424B5-FINAL 0001564590-21-059913 333-254193 211482781 33 906875
2021-12-07 424B5 424B5 0001564590-21-059603 333-254193 211476425 33 945726
2021-12-06 8-K 8-K 8.01 0000950170-21-005044 001-38359 211472016 34 207151 1 1
2021-11-18 4 FORM 4 SUBMISSION 0001209191-21-065375 5350
2021-11-18 3 FORM 3 SUBMISSION 0001209191-21-065374 7578
2021-11-18 8-K 8-K 5.02,7.01,9.01 0000950170-21-004750 001-38359 211422591 34 205795 1 1
2021-11-12 8-K 8-K 7.01,8.01,9.01 0000950170-21-004230 001-38359 211399541 34 221553 1 1
2021-11-10 10-Q 10-Q 0000950170-21-004111 001-38359 211397062 34 11395822 1 1
2021-11-10 8-K 8-K 2.02,9.01 0000950170-21-004083 001-38359 211396726 34 355175 1 1
2021-10-29 8-K 8-K 1.02 0000950170-21-002521 001-38359 211364070 34 179397 1 1
2021-10-25 8-K 8-K 1.01,9.01 0000950170-21-002279 001-38359 211344550 34 377825 1 1
2021-10-14 3/A FORM 3/A SUBMISSION 0001209191-21-060487 9410
2021-10-13 3 FORM 3 SUBMISSION 0001209191-21-060361 4474
2021-10-13 4 FORM 4 SUBMISSION 0001209191-21-060360 7797
2021-10-05 4 FORM 4 SUBMISSION 0001209191-21-059577 5315
2021-10-05 4 FORM 4 SUBMISSION 0001209191-21-059574 5289
2021-10-05 4 FORM 4 SUBMISSION 0001209191-21-059571 5287
2021-10-05 4 FORM 4 SUBMISSION 0001209191-21-059569 5334
2021-09-13 8-K 8-K 7.01,8.01,9.01 0000950170-21-001776 001-38359 211248682 34 267629 1 1
2021-08-16 10-K/A 10-K/A 0001564590-21-044668 001-38359 211179131 34 439415 1 1
2021-08-12 S-8 S-8 0001564590-21-044032 333-258763 211168360 33 151296
2021-08-12 10-Q 10-Q 0000950170-21-001381 001-38359 211168254 34 9948788 1 1
2021-08-12 8-K 8-K 2.02,9.01 0000950170-21-001371 001-38359 211167834 34 327097 1 1
2021-07-30 8-K 8-K 1.02 0000950170-21-000624 001-38359 211132616 34 174521 1 1
2021-07-23 8-K 8-K 1.01,9.01 0001564590-21-037772 001-38359 211111896 34 529354 1 1
2021-07-01 8-K 8-K 1.01,9.01 0000950170-21-000417 001-38359 211066050 34 766242 1 1
2021-06-21 4 FORM 4 SUBMISSION 0001209191-21-042000 7248
2021-06-17 4 FORM 4 SUBMISSION 0001209191-21-041630 9156
2021-06-14 4 FORM 4 SUBMISSION 0001209191-21-040232 5468
2021-06-08 4 FORM 4 SUBMISSION 0001209191-21-039073 7667
2021-06-07 4 FORM 4 SUBMISSION 0001209191-21-038758 7248
2021-05-21 EFFECT xslEFFECTX01/primary_doc.xml S-3,,2021-05-21 16:01:00 9999999995-21-002067 333-256088 21950970 33 1787
2021-05-21 4 FORM 4 SUBMISSION 0001209191-21-034929 10982
2021-05-21 424B3 424B3 0001564590-21-029312 333-256088 21949272 33 539844
2021-05-20 4 FORM 4 SUBMISSION 0001209191-21-034631 13622
2021-05-19 CORRESP filename1.htm 0001193125-21-166585 5797
2021-05-18 UPLOAD filename1.pdf 0000000000-21-006269 40243
2021-05-17 8-K/A 8-K/A 2.02,5.02,9.01 0001564590-21-028402 001-38359 21930964 34 262375 1 1
2021-05-17 10-Q 10-Q 0001564590-21-028185 001-38359 21927596 34 9605600 1 1
2021-05-17 8-K 8-K 2.02,5.02,9.01 0001564590-21-028180 001-38359 21927561 34 257632 1 1
2021-05-14 4 FORM 4 SUBMISSION 0001209191-21-032740 9809
2021-05-13 S-3 S-3 0001564590-21-027577 333-256088 21919974 33 708054
2021-05-07 4 FORM 4 SUBMISSION 0001209191-21-030874 10985

Latest XBRL company facts

One latest value per concept from companyfacts (386 concepts). Full history stays in the JSON.

TaxonomyTagLabelUnitValueStartEndFYFPFormFiledAccn
dei EntityCommonStockSharesOutstanding Entity Common Stock, Shares Outstanding shares 9.36M 2026-11-03 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
dei EntityPublicFloat Entity Public Float USD 50.50M 2025-06-30 2025 FY 10-K/A 2026-05-20 0001720580-26-000042
ecd NonPeoNeoAvgCompActuallyPaidAmt NonPeoNeoAvgCompActuallyPaidAmt USD 829,146 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001720580-26-000027
ecd NonPeoNeoAvgTotalCompAmt NonPeoNeoAvgTotalCompAmt USD 1.02M 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001720580-26-000027
ecd PeoActuallyPaidCompAmt PeoActuallyPaidCompAmt USD 347,816 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001720580-26-000027
ecd PeoTotalCompAmt PeoTotalCompAmt USD 1.47M 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001720580-26-000027
ecd TotalShareholderRtnAmt TotalShareholderRtnAmt USD 5.89 2025-01-01 2025-12-31 DEF 14A 2026-04-29 0001720580-26-000027
srt FinancingReceivableNonaccrualToOutstandingPercent FinancingReceivableNonaccrualToOutstandingPercent pure 1 2021-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap AccountsPayableCurrent Accounts Payable, Current USD 2.70M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AccountsReceivableRelatedPartiesCurrent Accounts Receivable, Related Parties, Current USD 0 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap AccretionAmortizationOfDiscountsAndPremiumsInvestments Accretion (Amortization) of Discounts and Premiums, Investments USD 1.93M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AccruedLiabilitiesAndOtherLiabilities Accrued Liabilities and Other Liabilities USD 11.45M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AccruedLiabilitiesCurrent Accrued Liabilities, Current USD 1.10M 2020-06-30 2020 Q2 10-Q 2020-07-30 0001564590-20-034835
us-gaap AccruedProfessionalFeesCurrentAndNoncurrent Accrued Professional Fees USD 1.03M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AccumulatedAmortizationDeferredFinanceCosts Accumulated Amortization, Debt Issuance Costs USD 0 2021-06-30 2021 Q2 10-Q 2021-08-12 0000950170-21-001381
us-gaap AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment USD 30.97M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AccumulatedOtherComprehensiveIncomeLossNetOfTax Accumulated Other Comprehensive Income (Loss), Net of Tax USD -175,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AdditionalPaidInCapital Additional Paid in Capital USD 175.63M 2018-12-31 2018 FY 10-K 2019-03-18 0001564590-19-008262
us-gaap AdditionalPaidInCapitalCommonStock Additional Paid in Capital, Common Stock USD 778.05M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Share-based Payment Arrangement, Decrease for Tax Withholding Obligation USD 1.35M 2022-07-01 2022-09-30 2022 Q3 10-Q 2022-11-08 0000950170-22-023230
us-gaap AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock USD -1.38M 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD 1.51M 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD 600,000 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap AdjustmentsToAdditionalPaidInCapitalWarrantIssued Adjustments to Additional Paid in Capital, Warrant Issued USD 22,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AdministrativeFeesExpense Administrative Fees Expense USD 10.00M 2024-01-01 2024-12-31 2026 Q2 10-Q 2026-08-05 0001720580-26-000050
us-gaap AllocatedShareBasedCompensationExpense Share-based Payment Arrangement, Expense USD 4.25M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits Dilutive Securities, Effect on Basic Earnings Per Share, Options and Restrictive Stock Units USD 5.38B 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0000950170-22-009690
us-gaap AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount shares 1.66M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AreaOfRealEstateProperty Area of Real Estate Property sqft 9,501 2019-04-01 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap AssetImpairmentCharges Asset Impairment Charges USD 0 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap Assets Assets USD 128.95M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AssetsCurrent Assets, Current USD 103.44M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax USD 175,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AvailableForSaleDebtSecuritiesAmortizedCostBasis Debt Securities, Available-for-sale, Amortized Cost USD 74.01M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AvailableForSaleSecuritiesAmortizedCost Available-for-sale Securities, Amortized Cost Basis USD 10.26M 2020-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value USD 92.52M 2018-09-30 2018 Q3 10-Q 2018-11-13 0001564590-18-029327
us-gaap AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One USD 10.26M 2020-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One USD 10.28M 2020-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap AvailableForSaleSecuritiesDebtSecurities Debt Securities, Available-for-sale USD 73.83M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap AvailableForSaleSecuritiesDebtSecuritiesCurrent Debt Securities, Available-for-sale, Current USD 0 2021-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap AvailableForSaleSecuritiesDebtSecuritiesNoncurrent Debt Securities, Available-for-sale, Noncurrent USD 0 2020-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap BusinessAcquisitionsProFormaNetIncomeLoss Business Acquisition, Pro Forma Net Income (Loss) USD -35.76M 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap BusinessCombinationContingentConsiderationLiability Business Combination, Contingent Consideration, Liability USD 980,000 2020-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage pure 0.75 2020-09-15 2021 Q2 10-Q 2021-08-12 0000950170-21-001381
us-gaap CapitalExpendituresIncurredButNotYetPaid Capital Expenditures Incurred but Not yet Paid USD 28,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap CashAcquiredFromAcquisition Cash Acquired from Acquisition USD 64.11M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap CashAndCashEquivalentsAtCarryingValue Cash and Cash Equivalents, at Carrying Value USD 27.11M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap CashAndCashEquivalentsPeriodIncreaseDecrease Cash and Cash Equivalents, Period Increase (Decrease) USD 16.58M 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-05 0001564590-19-040353
us-gaap CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments USD 91.50M 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents USD 29.68M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect USD -12.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Class of Warrant or Right, Exercise Price of Warrants or Rights USD/shares 0 2026-04-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding shares 0 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap CommonStockCapitalSharesReservedForFutureIssuance Common Stock, Capital Shares Reserved for Future Issuance shares 3.42M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap CommonStockDividendsPerShareCashPaid Common Stock, Dividends, Per Share, Cash Paid USD/shares 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap CommonStockDividendsPerShareDeclared Common Stock, Dividends, Per Share, Declared USD/shares 0 2020-01-01 2020-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034587
us-gaap CommonStockParOrStatedValuePerShare Common Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap CommonStockSharesAuthorized Common Stock, Shares Authorized shares 300.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap CommonStockSharesIssued Common Stock, Shares, Issued shares 9.59M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap CommonStockSharesOutstanding Common Stock, Shares, Outstanding shares 9.36M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap CommonStockSharesSubscribedButUnissued Common Stock, Shares Subscribed but Unissued shares 4.38M 2025-10-07 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap CommonStockValue Common Stock, Value, Issued USD 1,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ComprehensiveIncomeNetOfTax Comprehensive Income (Loss), Net of Tax, Attributable to Parent USD -60.76M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ConstructionInProgressGross Construction in Progress, Gross USD 500,000 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061128
us-gaap ConstructionPayableCurrentAndNoncurrent Construction Payable USD 13.80M 2022-03-18 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap ContractWithCustomerLiabilityCurrent Contract with Customer, Liability, Current USD 0 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap ContractWithCustomerLiabilityNoncurrent Contract with Customer, Liability, Noncurrent USD 10.89M 2019-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap ConversionOfStockAmountConverted1 Conversion of Stock, Amount Converted USD 2.92M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap ConvertiblePreferredStockSharesIssuedUponConversion Convertible Preferred Stock, Shares Issued upon Conversion shares 12.05M 2019-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap CostsAndExpenses Costs and Expenses USD 85.46M 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap CurrentFederalTaxExpenseBenefit Current Federal Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap CurrentForeignTaxExpenseBenefit Current Foreign Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap CurrentIncomeTaxExpenseBenefit Current Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap CurrentStateAndLocalTaxExpenseBenefit Current State and Local Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap CustomerAdvancesCurrent Customer Advances, Current USD 500,000 2018-09-30 2018 Q3 10-Q 2018-11-13 0001564590-18-029327
us-gaap DebtConversionConvertedInstrumentAmount1 Debt Conversion, Converted Instrument, Amount USD 114.08M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap DeferredCostsCurrent Deferred Costs, Current USD 929,000 2017-12-31 2018 FY 10-K 2019-03-18 0001564590-19-008262
us-gaap DeferredFederalIncomeTaxExpenseBenefit Deferred Federal Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap DeferredFinanceCostsGross Debt Issuance Costs, Gross USD 400,000 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap DeferredFinanceCostsNet Debt Issuance Costs, Net USD 100,000 2021-03-31 2021 Q1 10-Q 2021-05-17 0001564590-21-028185
us-gaap DeferredForeignIncomeTaxExpenseBenefit Deferred Foreign Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap DeferredIncomeTaxesAndTaxCredits Deferred Income Taxes and Tax Credits USD 28,000 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033482
us-gaap DeferredIncomeTaxExpenseBenefit Deferred Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap DeferredIncomeTaxLiabilities Deferred Tax Liabilities, Gross USD 125,000 2020-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap DeferredIncomeTaxLiabilitiesNet Deferred Income Tax Liabilities, Net USD 125,000 2020-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap DeferredOfferingCosts Deferred Offering Costs USD 0 2018-12-31 2018 FY 10-K 2019-03-18 0001564590-19-008262
us-gaap DeferredRentCreditNoncurrent Deferred Rent Credit, Noncurrent USD 234,000 2019-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap DeferredRevenueRevenueRecognized1 Deferred Revenue, Revenue Recognized USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033482
us-gaap DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred State and Local Income Tax Expense (Benefit) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap DeferredTaxAssetsDeferredIncome Deferred Tax Assets, Deferred Income USD 0 2023-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033482
us-gaap DeferredTaxAssetsGoodwillAndIntangibleAssets Deferred Tax Assets, Goodwill and Intangible Assets USD 541,000 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap DeferredTaxAssetsGross Deferred Tax Assets, Gross USD 143.13M 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap DeferredTaxAssetsInProcessResearchAndDevelopment Deferred Tax Assets, in Process Research and Development USD 26,000 2022-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033482
us-gaap DeferredTaxAssetsLiabilitiesNet Deferred Tax Assets, Net USD 0 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap DeferredTaxAssetsNet Deferred Tax Assets, Net of Valuation Allowance USD 2.60M 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap DeferredTaxAssetsOperatingLossCarryforwards Deferred Tax Assets, Operating Loss Carryforwards USD 103.03M 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap DeferredTaxAssetsOtherComprehensiveLoss Deferred Tax Assets, Other Comprehensive Loss USD 11,000 2018-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap DeferredTaxAssetsTaxCreditCarryforwardsResearch Deferred Tax Assets, Tax Credit Carryforwards, Research USD 4.15M 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost USD 3.04M 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals USD 1.04M 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap DeferredTaxAssetsValuationAllowance Deferred Tax Assets, Valuation Allowance USD 140.53M 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap DeferredTaxLiabilitiesOtherComprehensiveIncome Deferred Tax Liabilities, Other Comprehensive Income USD 13,000 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap DefinedContributionPlanEmployerDiscretionaryContributionAmount Defined Contribution Plan, Employer Discretionary Contribution Amount USD 1.10M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap Depreciation Depreciation USD 3.58M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap DepreciationAndAmortization Depreciation, Depletion and Amortization, Nonproduction USD 3.58M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap DevelopmentInProcess Development in Process USD 1.19M 2020-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap DilutiveSecuritiesEffectOnBasicEarningsPerShareOther Dilutive Securities, Effect on Basic Earnings Per Share, Dilutive Convertible Securities USD 538.66M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0000950170-22-009690
us-gaap DividendsPayableCurrentAndNoncurrent Dividends Payable USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap DueToRelatedPartiesCurrent Due to Related Parties, Current USD 0 2018-12-31 2018 FY 10-K 2019-03-18 0001564590-19-008262
us-gaap EarningsPerShareBasic Earnings Per Share, Basic USD/shares -5.62 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap EarningsPerShareBasicAndDiluted Earnings Per Share, Basic and Diluted USD/shares -2 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap EarningsPerShareDiluted Earnings Per Share, Diluted USD/shares -5.62 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent pure 0.21 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent pure -0.178 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent pure -0.006 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent pure -0.001 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent pure -0.025 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent pure -0.033 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Percent pure 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsForeign Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent pure 0 2020-01-01 2020-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap EffectiveIncomeTaxRateReconciliationTaxCreditsOther Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent pure -0.001 2024-01-01 2024-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap EmployeeBenefitsAndShareBasedCompensation Employee Benefits and Share-based Compensation USD 200,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current USD 4.90M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount USD 0 2020-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount USD 4.10M 2021-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap EquityMethodInvestmentOwnershipPercentage Equity Method Investment, Ownership Percentage pure 0.25 2021-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap FairValueAdjustmentOfWarrants Fair Value Adjustment of Warrants USD 897,000 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap FairValueAssetsLevel1ToLevel2TransfersAmount Fair Value, Assets, Level 1 to Level 2 Transfers, Amount USD 0 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap FairValueAssetsLevel2ToLevel1TransfersAmount Fair Value, Assets, Level 2 to Level 1 Transfers, Amount USD 0 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap FairValueLiabilitiesLevel1ToLevel2TransfersAmount Fair Value, Liabilities, Level 1 to Level 2 Transfers, Amount USD 0 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap FairValueLiabilitiesLevel2ToLevel1TransfersAmount Fair Value, Liabilities, Level 2 to Level 1 Transfers, Amount USD 0 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap FairValueOfAssetsAcquired Fair Value of Assets Acquired USD 84.14M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap FinanceLeaseInterestExpense Finance Lease, Interest Expense USD 23,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap FinanceLeaseLiability Finance Lease, Liability USD 806,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap FinanceLeaseLiabilityCurrent Finance Lease, Liability, Current USD 174,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap FinanceLeaseLiabilityNoncurrent Finance Lease, Liability, Noncurrent USD 632,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap FinanceLeaseLiabilityPaymentsDue Finance Lease, Liability, Payment, Due USD 1.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap FinanceLeaseLiabilityPaymentsDueInNextRollingTwelveMonths Finance Lease, Liability, Payments, Due in Next Rolling Twelve Months USD 250,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap FinanceLeaseLiabilityPaymentsDueInRollingAfterYearFive Finance Lease, Liability, Payments, Due in Rolling after Year Five USD 0 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap FinanceLeaseLiabilityPaymentsDueInRollingYearFive Finance Lease, Liability, Payments, Due in Rolling Year Five USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap FinanceLeaseLiabilityPaymentsDueInRollingYearFour Finance Lease, Liability, Payments, Due in Rolling Year Four USD 250,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap FinanceLeaseLiabilityPaymentsDueInRollingYearThree Finance Lease, Liability, Payments, Due in Rolling Year Three USD 250,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap FinanceLeaseLiabilityPaymentsDueInRollingYearTwo Finance Lease, Liability, Payments, Due in Rolling Year Two USD 250,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear Finance Lease, Liability, to be Paid, Remainder of Fiscal Year USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap FinanceLeaseLiabilityUndiscountedExcessAmount Finance Lease, Liability, Undiscounted Excess Amount USD 194,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap FinanceLeasePrincipalPayments Finance Lease, Principal Payments USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap FinanceLeaseRightOfUseAsset Finance Lease, Right-of-Use Asset, after Accumulated Amortization USD 854,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap FinanceLeaseRightOfUseAssetAmortization Finance Lease, Right-of-Use Asset, Amortization USD 200,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap FinanceLeaseWeightedAverageDiscountRatePercent Finance Lease, Weighted Average Discount Rate, Percent pure 0.1 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap GainLossOnDispositionOfAssets1 Gain (Loss) on Disposition of Assets USD 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap GainLossOnDispositionOfIntangibleAssets Gain (Loss) on Disposition of Intangible Assets USD 200,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap GainsLossesOnSalesOfAssets Gain (Loss) on Disposition of Assets for Financial Service Operations USD 100,000 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap GeneralAndAdministrativeExpense General and Administrative Expense USD 12.11M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap Goodwill Goodwill USD 0 2023-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033482
us-gaap GoodwillImpairedAccumulatedImpairmentLoss Goodwill, Impaired, Accumulated Impairment Loss USD 0 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034587
us-gaap GoodwillImpairmentLoss Goodwill, Impairment Loss USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034587
us-gaap ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest USD -60.34M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap IncomeTaxesPaid Income Taxes Paid USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap IncomeTaxesReceivable Income Taxes Receivable, Current USD 0 2021-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap IncomeTaxExaminationPenaltiesAndInterestAccrued Income Tax Examination, Penalties and Interest Accrued USD 0 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap IncomeTaxExpenseBenefit Income Tax Expense (Benefit) USD 144,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount USD 20.79M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap IncomeTaxReconciliationChangeInEnactedTaxRate Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount USD 2.20M 2017-01-01 2017-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap IncomeTaxReconciliationForeignIncomeTaxRateDifferential Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount USD 715,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount USD -24.53M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap IncomeTaxReconciliationNondeductibleExpenseOther Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount USD 103,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount USD 2.92M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap IncomeTaxReconciliationOtherAdjustments Effective Income Tax Rate Reconciliation, Other Adjustments, Amount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap IncomeTaxReconciliationStateAndLocalIncomeTaxes Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap IncomeTaxReconciliationTaxCredits Effective Income Tax Rate Reconciliation, Tax Credit, Amount USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap IncreaseDecreaseInAccountsPayable Increase (Decrease) in Accounts Payable USD -2.03M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap IncreaseDecreaseInAccountsReceivable Increase (Decrease) in Accounts Receivable USD 10.00M 2020-01-01 2020-06-30 2021 Q2 10-Q 2021-08-12 0000950170-21-001381
us-gaap IncreaseDecreaseInAccountsReceivableRelatedParties Increase (Decrease) in Accounts Receivable, Related Parties USD 0 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061128
us-gaap IncreaseDecreaseInAccruedLiabilities Increase (Decrease) in Accrued Liabilities USD -4.39M 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-07-30 0001564590-20-034835
us-gaap IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities USD -2.05M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap IncreaseDecreaseInConstructionPayables Increase (Decrease) in Construction Payables USD 8.80M 2023-01-01 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061128
us-gaap IncreaseDecreaseInContractWithCustomerLiability Increase (Decrease) in Contract with Customer, Liability USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033482
us-gaap IncreaseDecreaseInCustomerAdvances Increase (Decrease) in Customer Advances USD 500,000 2018-01-01 2018-09-30 2018 Q3 10-Q 2018-11-13 0001564590-18-029327
us-gaap IncreaseDecreaseInDeferredLiabilities Increase (Decrease) in Deferred Liabilities USD -119,000 2020-01-01 2020-09-30 2021 Q3 10-Q 2021-11-10 0000950170-21-004111
us-gaap IncreaseDecreaseInOtherNoncurrentAssets Increase (Decrease) in Other Noncurrent Assets USD 1,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap IncreaseDecreaseInOtherNoncurrentLiabilities Increase (Decrease) in Other Noncurrent Liabilities USD -9,000 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap IncreaseDecreaseInOtherOperatingLiabilities Increase (Decrease) in Other Operating Liabilities USD 1,000 2020-01-01 2020-09-30 2020 Q3 10-Q 2020-11-05 0001564590-20-051476
us-gaap IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets Increase (Decrease) in Prepaid Expense and Other Assets USD 102,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap IncreaseDecreaseInRestrictedCash Increase (Decrease) in Restricted Cash USD 161,000 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-05 0001564590-19-040353
us-gaap IntangibleAssetsNetExcludingGoodwill Intangible Assets, Net (Excluding Goodwill) USD 0 2021-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap InterestAndOtherIncome Interest and Other Income USD 3.48M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap InterestExpense Interest Expense USD 68,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap InterestIncomeOperating Interest Income, Operating USD 3.48M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap InterestReceivableCurrent Interest Receivable, Current USD 297,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap InvestmentIncomeNonoperating Investment Income, Nonoperating USD 2.82M 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap LeaseAndRentalExpense Operating Leases, Rent Expense USD 200,000 2020-01-01 2020-03-31 2021 Q1 10-Q 2021-05-17 0001564590-21-028185
us-gaap LeaseCost Lease, Cost USD 858,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap LeaseholdImprovementsGross Leasehold Improvements, Gross USD 18.40M 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap LesseeOperatingLeaseLiabilityPaymentsDue Lessee, Operating Lease, Liability, to be Paid USD 13.01M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five USD 0 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four USD 662,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three USD 3.91M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two USD 3.81M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months USD 3.71M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year USD 921,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Lessee, Operating Lease, Liability, Undiscounted Excess Amount USD 1.72M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap LettersOfCreditOutstandingAmount Letters of Credit Outstanding, Amount USD 200,000 2019-04-30 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap Liabilities Liabilities USD 26.25M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap LiabilitiesAndStockholdersEquity Liabilities and Equity USD 128.95M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap LiabilitiesCurrent Liabilities, Current USD 17.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap LitigationReserve Estimated Litigation Liability USD 0 2020-03-31 2020 Q1 10-Q 2020-05-07 0001564590-20-022817
us-gaap LitigationSettlementExpense Litigation Settlement, Expense USD 200,000 2020-10-01 2020-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap LoansReceivableBasisSpreadOnVariableRate Loans Receivable, Basis Spread on Variable Rate pure 0.05 2020-04-28 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap MarketableSecurities Marketable Securities USD 0 2023-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034587
us-gaap MarketableSecuritiesCurrent Marketable Securities, Current USD 0 2020-06-30 2020 Q2 10-Q 2020-07-30 0001564590-20-034835
us-gaap NetCashProvidedByUsedInFinancingActivities Net Cash Provided by (Used in) Financing Activities USD -6,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap NetCashProvidedByUsedInFinancingActivitiesContinuingOperations Net Cash Provided by (Used in) Financing Activities, Continuing Operations USD 89.94M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001564590-18-012984
us-gaap NetCashProvidedByUsedInInvestingActivities Net Cash Provided by (Used in) Investing Activities USD 47.13M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap NetCashProvidedByUsedInInvestingActivitiesContinuingOperations Net Cash Provided by (Used in) Investing Activities, Continuing Operations USD -278,000 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001564590-18-012984
us-gaap NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities USD -59.23M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap NetCashProvidedByUsedInOperatingActivitiesContinuingOperations Net Cash Provided by (Used in) Operating Activities, Continuing Operations USD -7.30M 2018-01-01 2018-03-31 2018 Q1 10-Q 2018-05-10 0001564590-18-012984
us-gaap NetIncomeLoss Net Income (Loss) Attributable to Parent USD -60.48M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap NetIncomeLossAvailableToCommonStockholdersBasic Net Income (Loss) Available to Common Stockholders, Basic USD -60.48M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap NetIncomeLossAvailableToCommonStockholdersDiluted Net Income (Loss) Available to Common Stockholders, Diluted USD -60.48M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap NoninterestExpenseOfferingCost Noninterest Expense Offering Cost USD 91.70M 2024-01-23 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap NotesReduction Notes Reduction USD 0 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0000950170-22-009690
us-gaap NumberOfOperatingSegments Number of Operating Segments Segment 1 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap NumberOfReportableSegments Number of Reportable Segments Segment 1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OperatingExpenses Operating Expenses USD 63.67M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OperatingIncomeLoss Operating Income (Loss) USD -63.67M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OperatingLeaseCost Operating Lease, Cost USD 2.70M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OperatingLeaseLiability Operating Lease, Liability USD 11.29M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OperatingLeaseLiabilityCurrent Operating Lease, Liability, Current USD 2.67M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OperatingLeaseLiabilityNoncurrent Operating Lease, Liability, Noncurrent USD 8.62M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OperatingLeasePayments Operating Lease, Payments USD 100,000 2026-01-01 2026-06-30 2026 Q2 10-Q 2026-08-05 0001720580-26-000050
us-gaap OperatingLeasePaymentsUse Operating Lease, Payments, Use USD 773,000 2023-07-01 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061128
us-gaap OperatingLeaseRightOfUseAsset Operating Lease, Right-of-Use Asset USD 8.93M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OperatingLeasesFutureMinimumPaymentsDue Operating Leases, Future Minimum Payments Due USD 27.02M 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061128
us-gaap OperatingLeasesFutureMinimumPaymentsDueCurrent Operating Leases, Future Minimum Payments Due, Next Twelve Months USD 5.01M 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061128
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFiveYears Operating Leases, Future Minimum Payments, Due in Five Years USD 2.88M 2019-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap OperatingLeasesFutureMinimumPaymentsDueInFourYears Operating Leases, Future Minimum Payments, Due in Four Years USD 12.09M 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061128
us-gaap OperatingLeasesFutureMinimumPaymentsDueInThreeYears Operating Leases, Future Minimum Payments, Due in Three Years USD 4.01M 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061128
us-gaap OperatingLeasesFutureMinimumPaymentsDueInTwoYears Operating Leases, Future Minimum Payments, Due in Two Years USD 4.66M 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061128
us-gaap OperatingLeasesFutureMinimumPaymentsDueThereafter Operating Leases, Future Minimum Payments, Due Thereafter USD 13.75M 2021-09-30 2021 Q3 10-Q 2021-11-10 0000950170-21-004111
us-gaap OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear Operating Leases, Future Minimum Payments, Remainder of Fiscal Year USD 1.24M 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061128
us-gaap OperatingLeasesRentExpenseMinimumRentals Operating Leases, Rent Expense, Minimum Rentals USD 600,000 2019-04-01 2019-04-30 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap OperatingLeasesRentExpenseSubleaseRentals1 Operating Leases, Rent Expense, Sublease Rentals USD 3.50M 2021-07-19 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap OperatingLeaseWeightedAverageDiscountRatePercent Operating Lease, Weighted Average Discount Rate, Percent pure 0.069 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OtherAccruedLiabilitiesCurrent Other Accrued Liabilities, Current USD 140,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OtherAssetImpairmentCharges Other Asset Impairment Charges USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap OtherAssetsCurrent Other Assets, Current USD 490,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OtherAssetsNoncurrent Other Assets, Noncurrent USD 80,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OtherComprehensiveIncomeLossBeforeTax Other Comprehensive Income (Loss), before Tax USD -277,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OtherComprehensiveIncomeLossNetOfTax Other Comprehensive Income (Loss), Net of Tax USD -70,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap OtherLiabilities Other Liabilities USD 115,000 2021-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap OtherLiabilitiesNoncurrent Other Liabilities, Noncurrent USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OtherNoncashExpense Other Noncash Expense USD 2.16M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OtherNonoperatingIncomeExpense Other Nonoperating Income (Expense) USD -83,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OtherOperatingIncomeExpenseNet Other Operating Income (Expense), Net USD 151,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap OtherShortTermInvestments Other Short-term Investments USD 73.83M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap PaymentsForRepurchaseOfCommonStock Payments for Repurchase of Common Stock USD 15.00M 2021-02-01 2021-02-28 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap PaymentsForRestructuring Payments for Restructuring USD 500,000 2020-01-01 2020-03-31 2020 Q1 10-Q 2020-05-07 0001564590-20-022817
us-gaap PaymentsOfDebtIssuanceCosts Payments of Debt Issuance Costs USD 22,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap PaymentsRelatedToTaxWithholdingForShareBasedCompensation Payment, Tax Withholding, Share-based Payment Arrangement USD 3,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap PaymentsToAcquireMarketableSecurities Payments to Acquire Marketable Securities USD 5.70M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap PaymentsToAcquirePropertyPlantAndEquipment Payments to Acquire Property, Plant, and Equipment USD 295,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap PreferredStockParOrStatedValuePerShare Preferred Stock, Par or Stated Value Per Share USD/shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap PreferredStockSharesAuthorized Preferred Stock, Shares Authorized shares 10.00M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap PreferredStockSharesIssued Preferred Stock, Shares Issued shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap PreferredStockSharesOutstanding Preferred Stock, Shares Outstanding shares 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap PreferredStockValue Preferred Stock, Value, Issued USD 0 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap PrepaidExpenseAndOtherAssetsCurrent Prepaid Expense and Other Assets, Current USD 2.50M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap PrepaidExpenseCurrent Prepaid Expense, Current USD 535,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap PrepaidInsurance Prepaid Insurance USD 128,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap PrepaidRent Prepaid Rent USD 221,000 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061128
us-gaap PrepaidTaxes Prepaid Taxes USD 76,000 2023-09-30 2023 Q3 10-Q 2023-11-08 0000950170-23-061128
us-gaap ProceedsFromIncomeTaxRefunds Proceeds from Income Tax Refunds USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap ProceedsFromIssuanceInitialPublicOffering Proceeds from Issuance Initial Public Offering USD 43.36M 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap ProceedsFromIssuanceOfCommonStock Proceeds from Issuance of Common Stock USD 0 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock Proceeds from Issuance of Redeemable Convertible Preferred Stock USD 76.92M 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap ProceedsFromIssuanceOfWarrants Proceeds from Issuance of Warrants USD 75.17M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale USD 0 2022-01-01 2022-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap ProceedsFromOtherShortTermDebt Proceeds from Other Short-term Debt USD 100,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ProceedsFromSaleAndMaturityOfMarketableSecurities Proceeds from Sale and Maturity of Marketable Securities USD 2.75M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap ProceedsFromSaleOfPropertyPlantAndEquipment Proceeds from Sale of Property, Plant, and Equipment USD 118,000 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap ProceedsFromStockOptionsExercised Proceeds from Stock Options Exercised USD 2,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ProceedsFromStockPlans Proceeds from Stock Plans USD 82,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ProfessionalAndContractServicesExpense Professional and Contract Services Expense USD 5.91M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ProfitLoss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest USD -60.48M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap PropertyPlantAndEquipmentGross Property, Plant and Equipment, Gross USD 44.03M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap PropertyPlantAndEquipmentNet Property, Plant and Equipment, Net USD 13.07M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ResearchAndDevelopmentExpense Research and Development Expense USD 51.56M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ResearchAndDevelopmentInProcess Research and Development in Process USD 1.00M 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-09 0000950170-23-019700
us-gaap RestrictedCash Restricted Cash USD 2.60M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap RestrictedCashNoncurrent Restricted Cash, Noncurrent USD 2.57M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap RestructuringAndRelatedCostExpectedCostRemaining1 Restructuring and Related Cost, Expected Cost Remaining USD 96,000 2020-03-31 2020 Q1 10-Q 2020-05-07 0001564590-20-022817
us-gaap RestructuringAndRelatedCostIncurredCost Restructuring and Related Cost, Incurred Cost USD 800,000 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-08 0000950170-22-023230
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminated Restructuring and Related Cost, Number of Positions Eliminated Employee 0 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-07-30 0001564590-20-034835
us-gaap RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent Restructuring and Related Cost, Number of Positions Eliminated, Period Percent pure 0.22 2019-01-01 2019-12-31 2020 Q2 10-Q 2020-07-30 0001564590-20-034835
us-gaap RestructuringCharges Restructuring Charges USD 100,000 2020-01-01 2020-06-30 2020 Q2 10-Q 2020-07-30 0001564590-20-034835
us-gaap RetainedEarningsAccumulatedDeficit Retained Earnings (Accumulated Deficit) USD -675.18M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap RevenueFromRelatedParties Revenue from Related Parties USD 0 2023-01-01 2023-03-31 2023 Q1 10-Q 2023-05-09 0000950170-23-019700
us-gaap RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability Right-of-Use Asset Obtained in Exchange for Finance Lease Liability USD 4,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability Right-of-Use Asset Obtained in Exchange for Operating Lease Liability USD 0 2023-01-01 2023-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033482
us-gaap SaleOfStockConsiderationReceivedOnTransaction Sale of Stock, Consideration Received on Transaction USD 94.20M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap SaleOfStockConsiderationReceivedPerTransaction Sale of Stock, Consideration Received Per Transaction USD 128.80M 2021-02-01 2021-02-28 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap SaleOfStockNumberOfSharesIssuedInTransaction Sale of Stock, Number of Shares Issued in Transaction shares 7.19M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap SaleOfStockPricePerShare Sale of Stock, Price Per Share USD/shares 16 2025-10-07 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap SecurityDepositLiability Security Deposit Liability USD 100,000 2021-07-19 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap ShareBasedCompensation Share-based Payment Arrangement, Noncash Expense USD 4.25M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage pure 0.75 2020-07-14 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate Share-based Compensation Arrangement by Share-based Payment Award, Discount from Market Price, Purchase Date pure 0.06 2025-10-07 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period shares 50,138 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value USD/shares 7.04 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number shares 65,461 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value USD/shares 37.81 2025-12-31 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate pure 0 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum pure 0.92 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum pure 0.9 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum pure 0.051 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum pure 0.036 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized shares 362,503 2021-09-30 2021 Q3 10-Q 2021-11-10 0000950170-21-004111
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant shares 560,000 2021-10-21 2022 Q2 10-Q 2022-08-10 0000950170-22-016254
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value USD 30,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number shares 554,361 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price USD/shares 38.56 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value USD 100,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period shares 210,524 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures shares 110,000 2026-06-01 2026-06-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross shares 1.04M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares shares 9,237 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value USD/shares 15.3 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price USD/shares 11.98 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value USD 226,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number shares 1.59M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price USD/shares 19.91 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value USD 226,000 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number shares 1.59M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price USD/shares 19.91 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares shares 22,282 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value USD/shares 53.83 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost Share-based Payment Arrangement, Plan Modification, Incremental Cost USD 300,000 2025-01-01 2025-09-30 2025 Q3 10-Q 2025-11-05 0001193125-25-266880
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price USD/shares 7.04 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price USD/shares 30.23 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price USD/shares 7.1 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap SharesIssuedPricePerShare Shares Issued, Price Per Share USD/shares 15.04 2025-10-07 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap ShortTermInvestments Short-term Investments USD 96.58M 2024-09-30 2024 Q3 10-Q 2024-11-06 0000950170-24-122253
us-gaap ShortTermLeaseCost Short-term Lease, Cost USD 34,000 2026-07-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants USD 220.89M 2022-01-01 2022-03-31 2022 Q1 10-Q 2022-05-12 0000950170-22-009690
us-gaap StockholdersEquity Stockholders' Equity Attributable to Parent USD 102.70M 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap StockholdersEquityNoteStockSplitConversionRatio1 Stockholders' Equity Note, Stock Split, Conversion Ratio pure 0.124 2020-09-15 2020 Q3 10-Q 2020-11-05 0001564590-20-051476
us-gaap StockIssuedDuringPeriodSharesOther Stock Issued During Period, Shares, Other shares 100,731 2022-04-30 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap StockIssuedDuringPeriodSharesRestrictedStockAwardGross Stock Issued During Period, Shares, Restricted Stock Award, Gross shares 0 2019-01-01 2019-09-30 2019 Q3 10-Q 2019-11-05 0001564590-19-040353
us-gaap StockIssuedDuringPeriodSharesReverseStockSplits Stock Issued During Period, Shares, Reverse Stock Splits shares 0 2020-09-15 2020 Q3 10-Q 2020-11-05 0001564590-20-051476
us-gaap StockIssuedDuringPeriodSharesStockOptionsExercised Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period shares 257 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap StockIssuedDuringPeriodValueConversionOfConvertibleSecurities Stock Issued During Period, Value, Conversion of Convertible Securities USD 114.08M 2020-01-01 2020-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap StockIssuedDuringPeriodValueEmployeeStockPurchasePlan Stock Issued During Period, Value, Employee Stock Purchase Plan USD 82,000 2026-04-01 2026-06-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap StockIssuedDuringPeriodValueNewIssues Stock Issued During Period, Value, New Issues USD 238.00M 2021-01-01 2021-12-31 2022 FY 10-K 2023-03-15 0000950170-23-008130
us-gaap StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures USD 1,000 2019-01-01 2019-03-31 2020 Q1 10-Q 2020-05-07 0001564590-20-022817
us-gaap StockIssuedDuringPeriodValueStockOptionsExercised Stock Issued During Period, Value, Stock Options Exercised USD 1,000 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased Stock Repurchase Program, Number of Shares Authorized to be Repurchased shares 1.15M 2021-02-28 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap SubleaseIncome Sublease Income USD 400,000 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit) USD 0 2017-12-22 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap TemporaryEquityAccretionToRedemptionValue Temporary Equity, Accretion to Redemption Value USD 0 2017-01-01 2017-12-31 2018 FY 10-K 2019-03-18 0001564590-19-008262
us-gaap TemporaryEquityCarryingAmountAttributableToParent Temporary Equity, Carrying Amount, Attributable to Parent USD 114.08M 2019-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap TemporaryEquityLiquidationPreference Temporary Equity, Liquidation Preference USD 128.19M 2019-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap TemporaryEquitySharesAuthorized Temporary Equity, Shares Authorized shares 99.36M 2019-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap UnrecognizedTaxBenefits Unrecognized Tax Benefits USD 32.10M 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions USD 5.73M 2025-01-01 2025-12-31 2025 FY 10-K 2026-03-12 0001720580-26-000008
us-gaap UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions USD 2,000 2022-01-01 2022-12-31 2023 FY 10-K 2024-03-19 0000950170-24-033482
us-gaap UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense USD 0 2019-01-01 2019-12-31 2019 FY 10-K 2020-03-12 0001564590-20-010474
us-gaap UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions USD 0 2024-01-01 2024-12-31 2024 FY 10-K 2025-03-06 0000950170-25-034587
us-gaap VariableLeaseCost Variable Lease, Cost USD 0 2022-01-01 2022-09-30 2022 Q3 10-Q 2022-11-08 0000950170-22-023230
us-gaap WarrantsAndRightsOutstanding Warrants and Rights Outstanding USD 2.90M 2020-09-15 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap WeightedAverageLimitedPartnershipUnitsOutstandingDiluted Weighted Average Limited Partnership Units Outstanding, Diluted shares 10.75M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap WeightedAverageNumberOfDilutedSharesOutstanding Weighted Average Number of Shares Outstanding, Diluted shares 10.75M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap WeightedAverageNumberOfShareOutstandingBasicAndDiluted Weighted Average Number of Shares Outstanding, Basic and Diluted shares 30.95M 2021-01-01 2021-12-31 2021 FY 10-K 2022-03-15 0000950170-22-003753
us-gaap WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation shares 9,344 2019-01-01 2019-12-31 2020 FY 10-K 2021-03-12 0001564590-21-012664
us-gaap WeightedAverageNumberOfSharesIssuedBasic Weighted Average Number of Shares Issued, Basic shares 10.75M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066
us-gaap WeightedAverageNumberOfSharesOutstandingBasic Weighted Average Number of Shares Outstanding, Basic shares 10.75M 2026-01-01 2026-09-30 2026 Q3 10-Q 2026-11-05 0001720580-26-000066

Financialist News Desk

Our desk turns official SEC filings into news. Each story is checked against the original filing. About us → · Editorial standards →